Results for this period
Full year1 March 2025–28 February 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Promotion of stores with in-store pharmacies, expansion of private-label products, appropriate control of selling, general and administrative expenses, stronger collaboration in product policy, merchandising, data utilization and store development functions following the management integration, and an increase in the number of stores associated with the conversion of companies into subsidiaries and other measures.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 March 2025–28 February 2026 |
| Net Sales | ¥1,450,585 million |
| Operating profit | ¥63,037 million |
| Ordinary income | ¥63,086 million |
| Profit attributable to owners of the parent | ¥42,670 million |
| Net income per share | ¥144.55 |
| Operating Margin | 4.3% |
| Equity ratio | End of the current fiscal period 53.1% / End of previous period 48.2% |
| Total assets | ¥1,647,981 million |
| Net assets | ¥895,706 million |
| Cash flows from operating activities | ¥84,582 million |
| Cash flows from investing activities | ¥-19,787 million |
| Cash flows from financing activities | ¥-39,047 million |
| Cash and cash equivalents at end of period | ¥201,309 million |
| Full-year earnings forecast | Net Sales ¥2,555,000 million (YoY +76.1%) / Operating profit ¥99,400 million (YoY +57.7%) / Ordinary income ¥98,100 million (YoY +55.5%) / Net income ¥41,500 million (YoY -2.7%) |
| Annual Dividend Forecast | ¥248.50 (actual for the fiscal year ended February 2026, before taking the stock split into account) → ¥48.00 (forecast for the fiscal year ending February 2027, after the stock split)（-3.4% (on a pre-stock-split basis)） |
| Payout ratio | Current fiscal year 34.4% / Next-year forecast 52.4% |
| Shareholder Return Policy | The company aims for a consolidated dividend payout ratio of at least 35% and will provide stable, progressive dividends. |
| Depreciation and amortization | ¥22,416 million |
| Impairment loss | ¥10,776 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 63 / Gain on sale of investment securities 6,742 / Gain on step acquisition 10,583 / Other 203 / Total extraordinary income 17,592 / Extraordinary loss Loss on Disposal of Fixed Assets 97 / Loss on sale of fixed assets 8 / Impairment loss 10,776 / Provision for store closure losses 2,929 / Other 541 / Total extraordinary loss 14,353 |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 18 companies (Welcia Holdings Co., Ltd. and 17 others) / Excluded 0 companies |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 454,308,990 |
| Treasury Shares at Period-End | 1,331,029 |
| Factors Behind Changes in Business Performance | Promotion of stores with in-store pharmacies, expansion of private-label products, appropriate control of selling, general and administrative expenses, stronger collaboration in product policy, merchandising, data utilization and store development functions following the management integration, and an increase in the number of stores associated with the conversion of companies into subsidiaries and other measures. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company cited the promotion of stores with in-store pharmacies, expansion of private-label products, appropriate control of selling, general and administrative expenses, stronger collaboration through management integration with Welcia Holdings Co., Ltd. and others, and an increase in the number of stores through the conversion of companies into subsidiaries and other measures.